No abstract

Introduction. Acute infectious rhinitis refers to the frequent causes of discharge therapy with nasal decongestants.   The aim to analyze the clinical features of unloading therapy of acute infectious rhinitis with 0.1 % xylometazoline according to the materials of the research centers of Novosibirsk and Yekaterinburg.   Materials and methods. In the research centers of Novosibirsk and Yekaterinburg, patients with acute infectious rhinitis were observed. Intranasal therapy in the study groups (group 1) and in the comparison groups (group 2) was carried out with 0.1 % xylometazoline spray for 7 days. Group 2 additionally received silver preparation intranasally. The need for decongestant and the state of mucociliary transport (MCT) were evaluated.   Results and discussion. Initially, patients with normal MCT rate at 1 visit in Novosibirsk accounted for 20.8 % in group 1 and 34.78 % in group 2; in Yekaterinburg – 29.17 % of patients in group 1 and 25% of patients in group 2. In the study groups, 54.2 % of patients in Novosibirsk and 100 % in Yekaterinburg used decongestant on day 5; in the comparison groups – 41.7% in Novosibirsk; 83.3% of patients in Yekaterinburg. On day 5, the volumetric air flow velocity was determined to be more than 900 cm3/s in all patients. Decongestant was used for more than 7 days by 40.35 % of patients in the first groups and 12.45 % of patients in the second groups. Inhibition of MCT on the 14 th day of follow-up, detected in two research centers, amounted to 5.26 % of patients.   Conclusions. On the 5th day of unloading therapy, nasal breathing is objectively free. Intranasal antiseptic therapy reduces the probability of using decongestant for more than 7 days by 27.9 %. Inhibition of MCT when using 0.1 % xylometazoline should be attributed to frequent reactions.

The task of treating any disease is to improve the quality of human life. However, there is no widespread practice in clinical studies to assess the health-related quality of life before and after medical intervention. The aim of the study was to evaluate the health-related quality of life in patients with bilateral laryngeal paralysis and the impact on the quality of life of methods of therapeutic rehabilitation of respiratory function using the international standardized questionnaire SF-36 (Russian version developed and recommended by the Multinational Center for Quality of Life Research (MCQLR)). A survey of 44 patients with bilateral laryngeal paralysis after a strumectomy lasting more than 1 year was conducted twice. The first questionnaire was conducted before the rehabilitation of respiratory function, the second questionnaire was conducted 4–6 months after rehabilitation. The patients underwent rehabilitation as part of two groups: in group 1, respiratory function rehabilitation was carried out by the method of prolonged injectable relaxation of the cricoid muscle with botulinum toxin type A. In group 2, respiratory function rehabilitation was carried out with phonopedic correction by the development of respiratory techniques and drug sedation with benzodiazepine. According to the results obtained, prolonged relaxation of the cricoid muscle by a single injection of botulinum toxin type A into the thickness of the cricoid muscle improves the physical component of the quality of life associated with health by 36%, the mental component, by 50%. Phonopedic correction will improve the physical component of the quality of life by 6%, and the mental component, by 4%. The obtained result can be used in communication between the patient and the doctor at the stage of explaining the effectiveness of available methods of conservative treatment for laryngeal paralysis.

No abstract

Introduction. Acute respiratory viral infections are the most widespread diseases, accounting for up to 90% of all infectious pathology, which supports the relevance of optimizing the treatment of acute viral rhinosinusitis.Aim. Evaluate the dynamics of clinical symptoms of acute viral rhinosinusitis, which arose as part of an acute respiratory infection, when supplementing therapy with the drug Respero Myrtol (Pol-Boskamp GmbH and Co.KG, Germany), the active ingredient of which is myrtol standardized 120 mg in 1 capsule.Materials and methods. The dynamics of clinical symptoms of 20 cases of acute viral rhinosinusitis in comparison groups was analyzed. Traditional treatment of patients included taking propionic acid derivatives, ascorbic acid, intranasal use of decongestants and irrigation of the nasal cavity with isotonic saline solutions. Patients who have received traditional treatment are defined as a “standard therapy group”. To assess the effectiveness of therapy using standardized myrtol, 20 cases of acute viral rhinosinusitis against the background of acute respiratory viral infections with a similar severity were analyzed, in which patients received outpatient therapy with Respero Myrtol 2 capsules 3 times a day for 7 days in addition to the above treatment (the “myrtol therapy” group). The dynamics of the disease assessed: the number of days of disability before recovery, the period of normalization of body temperature in feverish patients, the need for vasoconstrictive intranasal agents after the seventh day of therapy, the period of complete relief of pain syndrome, the period of normalization of night sleep, the number of cases of bacterial superinfection and the need for systemic antibacterial therapy.The results. In the observed patients, the quality of sleep was restored faster, the pain syndrome was stopped earlier, less often there was a need for systemic antibiotics and prolonged use of intranasal decongestants. The disease proceeded with fewer days of disability.Conclusion. The study results have been shown to report the clinical efficacy of Respero Myrtol essential oils in the outpatient treatment of patients with acute rhinosinusitis.